Tiziana Life Sciences Ltd. (0RP)
XMUN 
Summary
0RP Chart
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration
Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a potential leading treatment for neurodegenerative disease. The clinical-stage company is developing foralumab, an anti-CD3 antibody delivered via nasal spray, to stimulate regulatory T-cell (Treg) production and reduce the inflammatory processes that drive neurodegeneration.
Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday. The presentation, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial,” is scheduled for 4:30 pm to 6:30 pm Eastern Time during the Scientific Poster Session.
Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient in its Phase 2a clinical trial has received a first dose of intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS), with topline data expected in late Q3 or early Q4 2026. The company said results are planned to be presented at the 10th joint ACTRIMS-ECTRIMS meeting in Toronto in October 2026.
Tiziana Life Sciences Ltd. (0RP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tiziana Life Sciences Ltd. ever had a stock split?
Tiziana Life Sciences Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Ivor R. Elrifi CEO | XMUN Exchange | BMG889121031 ISIN |
| GB Country | 10 Employees | - Last Dividend | 29 Oct 2019 Last Split | 24 Mar 2000 IPO Date |
Overview
Tiziana Life Sciences Ltd is a biotechnology firm based in London, the United Kingdom, established in 1998. The company is dedicated to discovering and developing innovative molecules aimed at treating human diseases, with a primary focus on oncology and immunology. Leveraging advanced biotechnological methodologies, Tiziana Life Sciences is poised to address some of the most challenging medical conditions by advancing its research in monoclonal antibodies and small molecule inhibitors.
Products and Services
Foralumab (TZLS-401): Positioned as the company's forefront candidate in immunology, Foralumab is a groundbreaking human anti-CD3 monoclonal antibody (mAb). This therapeutic agent is being explored for its potential to treat a variety of autoimmune and inflammatory diseases, including Crohn's disease, graft-versus-host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. By targeting the CD3 antigen on T-lymphocytes, Foralumab is designed to modulate immune responses, offering hope for patients suffering from these chronic conditions.
Milciclib (TZLS-201): Milciclib represents another significant facet of Tiziana's developmental portfolio. As a small molecule inhibitor, Milciclib targets a range of cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases. These kinases are pivotal in the regulation of cell growth and the malignant progression of cancer. Through the inhibition of these kinases, Milciclib has the potential to stop cancer cells from growing and dividing uncontrollably, offering a strategic approach to cancer treatment.
Anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501): This fully human monoclonal antibody is designed to block the interleukin 6 (IL6) pathway, a critical mediator of inflammation and a known contributor to autoimmune diseases and cytokine release syndrome. By targeting IL6-induced inflammation, the anti-IL6R mAb presents a promising treatment avenue for conditions driven by excessive inflammation. Additionally, its application in treating COVID-19 patients by mitigating the severe respiratory symptoms associated with the virus demonstrates the versatility and potential impact of Tiziana's research in addressing urgent global health challenges.
